Giovanni Nocera

University of Pavia - Department of Economics and Management

Strada Nuova, 65

Pavia , 27100

Italy

SCHOLARLY PAPERS

3

DOWNLOADS

525

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (3)

1.

Spotlight on Biotechnology: From a Technological Breakthrough to Valuation Challenges. A Case Study on Crispr Therapeutics and Crispr/Cas 9 Revolution.

Number of pages: 40 Posted: 04 Dec 2020 Last Revised: 05 Dec 2020
University of Pavia - Department of Economics and Management, University of Pavia - Department of Economics and Management, University of Pavia - Department of Economics and Management and affiliation not provided to SSRNAcomeA SGR
Downloads 182 (224,836)

Abstract:

Loading...

Valuation, Real Options, Biotechnology, CRSPR

2.

A Journey Into the Biotechnology Industry: Valuation of Early-Stage Companies. Allakos’ Case Study and the Monoclonal Antibody Therapy

Number of pages: 24 Posted: 04 Dec 2020 Last Revised: 05 Dec 2020
University of Pavia - Department of Economics and Management, University of Pavia - Department of Economics and Management, University of Pavia - Department of Economics and Management and affiliation not provided to SSRNAcomeA SGR
Downloads 174 (233,614)

Abstract:

Loading...

Valuation, Real Options, Biotechnology

3.

Spotlight on Biotechnology: valuation challenges of early-stage companies. A case study on CRISPR Therapeutics AG and Allakos, Inc.

Number of pages: 36 Posted: 31 Dec 2020
University of Pavia - Department of Economics and Management, University of Pavia - Department of Economics and Management, University of Pavia - Department of Economics and Management and affiliation not provided to SSRNAcomeA SGR
Downloads 169 (239,425)

Abstract:

Loading...

Equity Valuation, Biotechnology, Volatility, Return, Stock pricing, Financial modelling, Value Investing, DCF, Real Option, Black & Scholes, CRISPR Therapeutics, Allakos, CRISPR, Cas9, Monoclonal Antibodies.